Christine E Ryan
Overview
Explore the profile of Christine E Ryan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Ryan C, Ren Y, Tyekucheva S, Arnason J, Boruchov A, Jacobson C, et al.
Hemasphere
. 2025 Jan;
9(1):e70067.
PMID: 39816532
No abstract available.
3.
Davids M, Ryan C, Lampson B, Ren Y, Tyekucheva S, Fernandes S, et al.
J Clin Oncol
. 2024 Dec;
43(7):788-799.
PMID: 39645236
Purpose: The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type ; however,...
4.
5.
Ryan C, Kumar A
Blood Rev
. 2024 Jun;
67:101221.
PMID: 38906740
Despite recent therapeutic advancements in the general field of non-Hodgkin lymphoma, effective treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL) remains a challenge. The development of Bruton tyrosine...
6.
Ryan C, Armand P, LaCasce A
Blood
. 2024 Mar;
145(7):663-672.
PMID: 38498174
Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. Treatments for patients with relapsed/refractory (R/R) disease are limited in number and in response durability. Therefore,...
7.
Ryan C, Jacobson C
Semin Hematol
. 2024 Jan;
60(5):322-328.
PMID: 38199906
Over the last decade, CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has profoundly changed the management of relapsed/refractory large-B-cell lymphoma (LBCL). At present, there are three FDA-approved anti-CD19 CAR T-cell...
8.
Chong S, Zhu F, Dashevsky O, Mizuno R, Lai J, Hackett L, et al.
J Clin Invest
. 2023 Sep;
133(22).
PMID: 37751299
The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid malignancies such as diffuse large B cell...
9.
Ryan C, Zon R, Redd R, Fisher D, Shouval R, Kumar A, et al.
Br J Haematol
. 2023 Aug;
203(5):774-780.
PMID: 37584155
Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients...
10.
Ryan C, Davids M
Am Soc Clin Oncol Educ Book
. 2023 May;
43:e390804.
PMID: 37141545
While the past decade has witnessed unprecedented progress for patients with chronic lymphocytic leukemia (CLL), outcomes for patients with Richter transformation (RT) remain dismal. Multiagent chemoimmunotherapy regimens, such as rituximab...